Periodontal DiseasesPhase 4Antiox-SRPNCT06894667
The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process: A Randomized Controlled Clinical Trial
A Phase 4 study testing Antioxidant gel and Antimicrobial gel in people with Periodontal Diseases, run by Kuwait University at 1 site in Kuwait.
Trial summary
This study aims to evaluate the comparative impact of chlorhexidine and antioxidant gel on postoperative biomarkers following SRP. By examining biomarkers related to inflammation, oxidative stress, and tissue healing, this research seeks to determine which treatment modality more effectively supports recovery and… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Diseases
- What is being tested?
- Antioxidant gel and Antimicrobial gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteKuwait
- Study dates
- 1 Nov 2024to 1 Dec 2025
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients with Stage 3 or 4 periodontitis would be invited to participate in this study.
- The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3.
Who cannot join
- Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months).
- Recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process Follow Scaling and Root Planing: A Randomized Controlled Clinical Trial
This study aims to evaluate the comparative impact of chlorhexidine and antioxidant gel on postoperative biomarkers following SRP. By examining biomarkers related to inflammation, oxidative stress, and tissue healing, this research seeks to determine which treatment modality more effectively supports recovery and reduces postoperative complications.
Understanding the differential effects of these interventions on postoperative biomarkers will contribute valuable insights into optimizing SRP outcomes. Correlations between biomarker levels and clinical outcomes, such as periodontal pocket depth and clinical attachment level changes will provide valuable information on the clinical relevance of the findings. This comparison will also guide clinicians in selecting the most appropriate postoperative care to enhance patient recovery and long-term periodontal health.
Read the detailed description
Background
Periodontitis is characterised by inflammation that results in the loss of periodontal attachment. Scaling and root planing (SRP) is a fundamental non-surgical treatment for periodontitis, which aims to remove the primary causative agents - dental plaque and calculus, from the tooth surfaces. Postoperative care is critical to ensure optimal healing and to manage potential inflammation and microbial load. Traditionally, chlorhexidine, an antimicrobial agent, has been utilized as an adjunctive treatment to prevent infection and manage inflammation following SRP. Chlorhexidine's broad-spectrum antimicrobial properties have been well-documented, and its application has been associated with reduced clinical symptoms and enhanced periodontal healing.
However, recent research has suggested potential benefits of antioxidant gels in promoting tissue repair and reducing oxidative stress, which could be beneficial in the postoperative period. Antioxidant gels, containing compounds such as vitamin C, vitamin E, or polyphenols, are proposed to mitigate oxidative damage and inflammation, potentially offering a different mechanism of action compared to traditional antimicrobial approaches.
Given these advances, there is a need to evaluate and compare the efficacy of chlorhexidine and antioxidant gels in managing postoperative outcomes following SRP. Specifically, assessing their impact on postoperative biomarkers, such as inflammatory cytokines, oxidative stress markers, and periodontal tissue regeneration indicators, could provide valuable insights into their relative effectiveness. In an animal model, found that animals treated with antioxidant gels healed faster and also led to an upregulation of TNFalpha and the antioxidant enzyme superoxide dismutase. However, to the best of our knowledge there are no human clinical studies that have established this relationship. Therefore, this study aims to compare the efficacy adjunctive treatment with chlorhexidine and antioxidant gels along with SRP in the management of patients with periodontitis.
Objectives The objectives of this study are to evaluate and compare the effects of chlorhexidine and antioxidant gel on inflammatory biomarkers (e.g.: Tumor Necrosis Factor-alpha (TNF-alpha); and antioxidant related markers (e.g.: Myeloperoxidase (MPO), among patients undergoing scaling and root planing (SRP). Additionally, the study aims to determine the clinical efficacy of these postoperative treatments in modulating the tissue response.
Methodology Ethics The present study will be performed following the guidelines of the Declaration of Helsinki as revised in 2013 for experimentation involving human patients. All volunteering individuals will be requested to read and sign a consent form written in simple Arabic and English and the study will be presented in accordance with the consolidation standards of reporting trails (CONSORT) guidelines. All participants will be informed that they can withdraw their participation at any phase of the study without consequence. Ethical approval will be obtained from Ethics Committee of Health Science Center at Kuwait University and Ministry of Health. Permission to recruit subjects for this study from the dental clinics of Jaber Hospital has been obtained from the Head of Clinics. The experimental protocol will be also registered at ClinicalTrial.gov.
Study Area/Setting
This prospective study will be conducted between March 2025 and June 2025 at the Dental Clinics of Jaber Hospital and at Kuwait University Dental Center. A convenient sample was selected from regular patients attending the dental clinics.
Grouping Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic plaque biofilms and characterised by the progressive destruction of the tooth-supporting apparatus. The definition of periodontitis will be based on the consensus report of Workgroup-4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. Patients with stage III and stage IV periodontitis will be included in this study. A total of 40 subjects would be divided into the following groups: Group-1: administration of chlorhexidine gel (n=20) and Group-2: administration of antioxidant gel (n=20).
The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3. Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months). Additionally, exclusion criteria include recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.
Questionnaire A standardized questionnaire will be used to gather information regarding age ( in years ), gender, medical, smoking, and oral health history, including the presence of systemic diseases ( Diabetes mellitus , hypertension ), smoking status, and any recent use of oral contraceptives, antibiotics, NSAIDs, bisphosphonates, or chlorhexidine. This will ensure accurate characterization of the study population and identification of any potential confounding factors. All participants will be asked about their daily tooth brushing habits and the date of the last dental visit and the procedure was done.
Clinical Procedure and Sample Collection All examiners involved in the clinical assessments, laboratory analysis, and statistical evaluations should ideally be blinded to avoid bias. At the initial baseline stage (T0), all participants will undergo non-surgical periodontal therapy, which entails plaque and calculus removal, the use of an ultrasonic scaler, and root planing with sterile curettes (Hu-Freiddy, Chicago, IL, USA). This procedure is expected to last about 60-90 minutes. After the non-surgical therapy, patients will be advised to follow routine oral hygiene practices. Participants will be divided into two groups: one group will receive chlorhexidine gel and the second group will be treated with an antioxidant gel (Tebodont®, Dr. Wild \& Co. AG, Basel). They will then be scheduled for a follow-up appointment 4 weeks later (T1).
Salivary Sample Collection The samples during T0 and T1 will be collected from the deepest pocket of the buccal side of the first or second molars as described in an earlier study.
Analysis of Salivary Biomarkers Samples will be stored at -80°C until ready for analysis. TNF-α and MPO will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Clinical and Radiographic Examination For all participants, the Löe \& Silness gingival index (GI) and Silness \& Löe plaque index (PI), bleeding on probing (BOP), and periodontal pocket depth (PD) will be measured on the mesiobuccal, midbuccal, distobuccal, distolingual/palatal, mid-lingual/palatal, and mesio-lingual/palatal surfaces of all maxillary and mandibular teeth by trained and calibrated examiners.
Statistical Analysis Sample size was determined using a computer software G*-power (version 3.0.10; Franz Faul Universitat, Kiel, Germany) based on the values from a previous study 6. It was determined that a sample of 18 individuals/group will be required to get an 80% power and detect the difference in the TNF-α levels between the groups. The Kolmogorov Smirnov-test will be used to assess the data normality and appropriate bivariate and multivariable models will be employed to analyze the data. The level of significance will be set to p<0.05. All the analyses will be carried out using SPSS 27.0 (IBM Corp. Released 2017.IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.).
- Conditions
- Periodontal Diseases
- Being tested
- Antioxidant gel, Antimicrobial gel
- Keywords
- Antioxidant, Scaling and root planing
- Medical subject headings
- Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antioxidant gelDrug
Also called Tea Tree oil (Tebodont®, Dr. Wild & Co. AG, Basel)
An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing
Antimicrobial gelDrug
Also called Chlorhexidine gel (PERIOPLUS+ FORTE, Curaprox, Curaden)
An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing
| Study group | Role | What they receive |
|---|---|---|
| Control Arm | Active comparator | A local gel containing 0.5% chlorhexidene (Curaprox Perioplus Focus Gel,PERIOPLUS+ FORTE, Curaprox, Curaden) would be administered Receives: Drug: Antimicrobial gel |
| Test Arm | Experimental | Commercially available antioxidant gel with Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be administered Receives: Drug: Antioxidant gel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plaque Index
to assess plaque accumulation
Measured: baseline
Plaque Index
to assess plaque accumulation
Measured: at 1 month post-intervention
Gingival index
for evaluating gingival inflammation
Measured: baseline
Gingival index
for evaluating gingival inflammation
Measured: at 1 month post-intervention
Probing pocket depth (PPD)
for measuring disease severity.PPD is measured in millimetres
Measured: baseline
Probing pocket depth (PPD)
for measuring disease severity. PPD is measured in millimetres
Measured: at 1 month post-intervention
Clinical attachment level
- Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Measured: baseline
Clinical attachment level
Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Measured: at 1 month post-intervention
Bleeding on probing (BoP)
to assess disease activity
Measured: baseline
Bleeding on probing (BoP)
to assess disease activity
Measured: at 1 month post-intervention
Secondary outcomes (4)
TNF-α salivary levels
TNF-α in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Measured: baseline
TNF-α salivary levels
TNF-α in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Measured: 1 month post intervention
MPO salivary levels
MPO in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Measured: baseline
MPO salivary levels
MPO in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Measured: 1 month post intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2025
- Study start1 Nov 2024
- Primary completion1 Sep 2025 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A total of 40 subjects would be divided into two groups: Group-1(Control): administration of chlorhexidine gel (n=20) and Group-2 (Test): administration of antioxidant gel (n=20).
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kuwait University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Jagan K Baskaradoss, Kuwait University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06894667
- Sponsor's protocol ID
- HSC_816
- Acronym
- Antiox-SRP
- Status last verified
- Mar 2025
- First submitted
- 23 Feb 2025
- Last updated
- 25 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data for the study will be maintained by the Principal investigator.
Publications
Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.
PubMed 32383274Martin BJ, Campbell PM, Rees TD, Buschang PH. A randomized controlled trial evaluating antioxidant-essential oil gel as a treatment for gingivitis in orthodontic patients. Angle Orthod. 2016 May;86(3):407-12. doi: 10.2319/041515-251.1. Epub 2015 Aug 17.
PubMed 26280662San Miguel SM, Opperman LA, Allen EP, Svoboda KK. Use of antioxidants in oral healthcare. Compend Contin Educ Dent. 2011 Nov-Dec;32(9):E156-9.
PubMed 23627309
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process Follow Scaling and Root Planing: A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT06894667
- Acronym / sponsor ID
- Antiox-SRP / HSC_816
- Conditions
- Periodontal Diseases
- Keywords
- Antioxidant, Scaling and root planing
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Kuwait UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 25 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the comparative impact of chlorhexidine and antioxidant gel on postoperative biomarkers following SRP. By examining biomarkers related to inflammation, oxidative stress, and tissue healing, this research seeks to determine which treatment modality more effectively supports recovery and reduces postoperative complications.
Understanding the differential effects of these interventions on postoperative biomarkers will contribute valuable insights into optimizing SRP outcomes. Correlations between biomarker levels and clinical outcomes, such as periodontal pocket depth and clinical attachment level changes will provide valuable information on the clinical relevance of the findings. This comparison will also guide clinicians in selecting the most appropriate postoperative care to enhance patient recovery and long-term periodontal health.
Detailed description
Background
Periodontitis is characterised by inflammation that results in the loss of periodontal attachment. Scaling and root planing (SRP) is a fundamental non-surgical treatment for periodontitis, which aims to remove the primary causative agents - dental plaque and calculus, from the tooth surfaces. Postoperative care is critical to ensure optimal healing and to manage potential inflammation and microbial load. Traditionally, chlorhexidine, an antimicrobial agent, has been utilized as an adjunctive treatment to prevent infection and manage inflammation following SRP. Chlorhexidine's broad-spectrum antimicrobial properties have been well-documented, and its application has been associated with reduced clinical symptoms and enhanced periodontal healing.
However, recent research has suggested potential benefits of antioxidant gels in promoting tissue repair and reducing oxidative stress, which could be beneficial in the postoperative period. Antioxidant gels, containing compounds such as vitamin C, vitamin E, or polyphenols, are proposed to mitigate oxidative damage and inflammation, potentially offering a different mechanism of action compared to traditional antimicrobial approaches.
Given these advances, there is a need to evaluate and compare the efficacy of chlorhexidine and antioxidant gels in managing postoperative outcomes following SRP. Specifically, assessing their impact on postoperative biomarkers, such as inflammatory cytokines, oxidative stress markers, and periodontal tissue regeneration indicators, could provide valuable insights into their relative effectiveness. In an animal model, found that animals treated with antioxidant gels healed faster and also led to an upregulation of TNFalpha and the antioxidant enzyme superoxide dismutase. However, to the best of our knowledge there are no human clinical studies that have established this relationship. Therefore, this study aims to compare the efficacy adjunctive treatment with chlorhexidine and antioxidant gels along with SRP in the management of patients with periodontitis.
Objectives The objectives of this study are to evaluate and compare the effects of chlorhexidine and antioxidant gel on inflammatory biomarkers (e.g.: Tumor Necrosis Factor-alpha (TNF-alpha); and antioxidant related markers (e.g.: Myeloperoxidase (MPO), among patients undergoing scaling and root planing (SRP). Additionally, the study aims to determine the clinical efficacy of these postoperative treatments in modulating the tissue response.
Methodology Ethics The present study will be performed following the guidelines of the Declaration of Helsinki as revised in 2013 for experimentation involving human patients. All volunteering individuals will be requested to read and sign a consent form written in simple Arabic and English and the study will be presented in accordance with the consolidation standards of reporting trails (CONSORT) guidelines. All participants will be informed that they can withdraw their participation at any phase of the study without consequence. Ethical approval will be obtained from Ethics Committee of Health Science Center at Kuwait University and Ministry of Health. Permission to recruit subjects for this study from the dental clinics of Jaber Hospital has been obtained from the Head of Clinics. The experimental protocol will be also registered at ClinicalTrial.gov.
Study Area/Setting
This prospective study will be conducted between March 2025 and June 2025 at the Dental Clinics of Jaber Hospital and at Kuwait University Dental Center. A convenient sample was selected from regular patients attending the dental clinics.
Grouping Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic plaque biofilms and characterised by the progressive destruction of the tooth-supporting apparatus. The definition of periodontitis will be based on the consensus report of Workgroup-4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. Patients with stage III and stage IV periodontitis will be included in this study. A total of 40 subjects would be divided into the following groups: Group-1: administration of chlorhexidine gel (n=20) and Group-2: administration of antioxidant gel (n=20).
The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3. Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months). Additionally, exclusion criteria include recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.
Questionnaire A standardized questionnaire will be used to gather information regarding age ( in years ), gender, medical, smoking, and oral health history, including the presence of systemic diseases ( Diabetes mellitus , hypertension ), smoking status, and any recent use of oral contraceptives, antibiotics, NSAIDs, bisphosphonates, or chlorhexidine. This will ensure accurate characterization of the study population and identification of any potential confounding factors. All participants will be asked about their daily tooth brushing habits and the date of the last dental visit and the procedure was done.
Clinical Procedure and Sample Collection All examiners involved in the clinical assessments, laboratory analysis, and statistical evaluations should ideally be blinded to avoid bias. At the initial baseline stage (T0), all participants will undergo non-surgical periodontal therapy, which entails plaque and calculus removal, the use of an ultrasonic scaler, and root planing with sterile curettes (Hu-Freiddy, Chicago, IL, USA). This procedure is expected to last about 60-90 minutes. After the non-surgical therapy, patients will be advised to follow routine oral hygiene practices. Participants will be divided into two groups: one group will receive chlorhexidine gel and the second group will be treated with an antioxidant gel (Tebodont®, Dr. Wild \& Co. AG, Basel). They will then be scheduled for a follow-up appointment 4 weeks later (T1).
Salivary Sample Collection The samples during T0 and T1 will be collected from the deepest pocket of the buccal side of the first or second molars as described in an earlier study.
Analysis of Salivary Biomarkers Samples will be stored at -80°C until ready for analysis. TNF-α and MPO will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).
Clinical and Radiographic Examination For all participants, the Löe \& Silness gingival index (GI) and Silness \& Löe plaque index (PI), bleeding on probing (BOP), and periodontal pocket depth (PD) will be measured on the mesiobuccal, midbuccal, distobuccal, distolingual/palatal, mid-lingual/palatal, and mesio-lingual/palatal surfaces of all maxillary and mandibular teeth by trained and calibrated examiners.
Statistical Analysis Sample size was determined using a computer software G*-power (version 3.0.10; Franz Faul Universitat, Kiel, Germany) based on the values from a previous study 6. It was determined that a sample of 18 individuals/group will be required to get an 80% power and detect the difference in the TNF-α levels between the groups. The Kolmogorov Smirnov-test will be used to assess the data normality and appropriate bivariate and multivariable models will be employed to analyze the data. The level of significance will be set to p<0.05. All the analyses will be carried out using SPSS 27.0 (IBM Corp. Released 2017.IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- A total of 40 subjects would be divided into two groups: Group-1(Control): administration of chlorhexidine gel (n=20) and Group-2 (Test): administration of antioxidant gel (n=20).
| Arm | Type | Receives |
|---|---|---|
| Control Arm | Active comparator | Drug: Antimicrobial gelA local gel containing 0.5% chlorhexidene (Curaprox Perioplus Focus Gel,PERIOPLUS+ FORTE, Curaprox, Curaden) would be administered |
| Test Arm | Experimental | Drug: Antioxidant gelCommercially available antioxidant gel with Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be administered |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Patients with Stage 3 or 4 periodontitis would be invited to participate in this study.
- The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3.
Key exclusion criteria (2 listed)
- Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months).
- Recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antioxidant gelAlso: Tea Tree oil (Tebodont®, Dr. Wild & Co. AG, Basel)An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing | Drug | Test Arm |
| Antimicrobial gelAlso: Chlorhexidine gel (PERIOPLUS+ FORTE, Curaprox, Curaden)An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing | Drug | Control Arm |
Primary outcome
Plaque Index
Time frame: baseline
to assess plaque accumulation
Plaque Index
Time frame: at 1 month post-intervention
to assess plaque accumulation
Gingival index
Time frame: baseline
for evaluating gingival inflammation
Gingival index
Time frame: at 1 month post-intervention
for evaluating gingival inflammation
Probing pocket depth (PPD)
Time frame: baseline
for measuring disease severity.PPD is measured in millimetres
Probing pocket depth (PPD)
Time frame: at 1 month post-intervention
for measuring disease severity. PPD is measured in millimetres
Clinical attachment level
Time frame: baseline
o Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Clinical attachment level
Time frame: at 1 month post-intervention
Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Bleeding on probing (BoP)
Time frame: baseline
to assess disease activity
Bleeding on probing (BoP)
Time frame: at 1 month post-intervention
to assess disease activity
4 secondary outcomes
TNF-α salivary levels
Time frame: baseline
TNF-α salivary levels
Time frame: 1 month post intervention
MPO salivary levels
Time frame: baseline
MPO salivary levels
Time frame: 1 month post intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2025.
- Results publication: PubMed 32383274Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.
- Results publication: PubMed 26280662Martin BJ, Campbell PM, Rees TD, Buschang PH. A randomized controlled trial evaluating antioxidant-essential oil gel as a treatment for gingivitis in orthodontic patients. Angle Orthod. 2016 May;86(3):407-12. doi: 10.2319/041515-251.1. Epub 2015 Aug 17.
- Results publication: PubMed 23627309San Miguel SM, Opperman LA, Allen EP, Svoboda KK. Use of antioxidants in oral healthcare. Compend Contin Educ Dent. 2011 Nov-Dec;32(9):E156-9.
- Individual participant dataSharing planned: No. The data for the study will be maintained by the Principal investigator.
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Antioxidant gel and Antimicrobial gel in people with Periodontal Diseases, run by Kuwait University at 1 site in Kuwait.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kuwait. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plaque Index (time frame: baseline). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06894667, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2025.